Search Results - "Kirschmeier, Paul T"

Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma by Iorgulescu, J Bryan, Gokhale, Prafulla C, Speranza, Maria C, Eschle, Benjamin K, Poitras, Michael J, Wilkens, Margaret K, Soroko, Kara M, Chhoeu, Chhayheng, Knott, Aine, Gao, Yan, Lim-Fat, Mary Jane, Baker, Gregory J, Bonal, Dennis M, Nguyen, Quang-Dé, Grant, Gareth R L, Ligon, Keith L, Sorger, Peter K, Chiocca, E Antonio, Anderson, Ana C, Kirschmeier, Paul T, Sharpe, Arlene H, Freeman, Gordon J, Reardon, David A

“…Dexamethasone, a uniquely potent corticosteroid, is frequently administered to patients with brain tumors to decrease tumor-associated edema, but limited data…”
Get full text

The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition by Parmar, Kalindi, Kochupurakkal, Bose S, Lazaro, Jean-Bernard, Wang, Zhigang C, Palakurthi, Sangeetha, Kirschmeier, Paul T, Yang, Chunyu, Sambel, Larissa A, Färkkilä, Anniina, Reznichenko, Elizaveta, Reavis, Hunter D, Dunn, Connor E, Zou, Lee, Do, Khanh T, Konstantinopoulos, Panagiotis A, Matulonis, Ursula A, Liu, Joyce F, D'Andrea, Alan D, Shapiro, Geoffrey I

“…PARP inhibitors are approved for the treatment of high-grade serous ovarian cancers (HGSOC). Therapeutic resistance, resulting from restoration of homologous…”
Get full text

Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics by Liu, Joyce F, Palakurthi, Sangeetha, Zeng, Qing, Zhou, Shan, Ivanova, Elena, Huang, Wei, Zervantonakis, Ioannis K, Selfors, Laura M, Shen, Yiping, Pritchard, Colin C, Zheng, Mei, Adleff, Vilmos, Papp, Eniko, Piao, Huiying, Novak, Marian, Fotheringham, Susan, Wulf, Gerburg M, English, Jessie, Kirschmeier, Paul T, Velculescu, Victor E, Paweletz, Cloud, Mills, Gordon B, Livingston, David M, Brugge, Joan S, Matulonis, Ursula A, Drapkin, Ronny

“…Ovarian cancer is the leading cause of death from gynecologic malignancy in the United States, with high rates of recurrence and eventual resistance to…”
Get full text

Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13 by Zeng, Mei, Kwiatkowski, Nicholas P, Zhang, Tinghu, Nabet, Behnam, Xu, Mousheng, Liang, Yanke, Quan, Chunshan, Wang, Jinhua, Hao, Mingfeng, Palakurthi, Sangeetha, Zhou, Shan, Zeng, Qing, Kirschmeier, Paul T, Meghani, Khyati, Leggett, Alan L, Qi, Jun, Shapiro, Geoffrey I, Liu, Joyce F, Matulonis, Ursula A, Lin, Charles Y, Konstantinopoulos, Panagiotis A, Gray, Nathanael S

“…High-grade serous ovarian cancer is characterized by extensive copy number alterations, among which the amplification of oncogene occurs in nearly half of…”
Get full text

EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody-Drug Conjugate HER3-DXd by Haikala, Heidi M, Lopez, Timothy, Köhler, Jens, Eser, Pinar O, Xu, Man, Zeng, Qing, Teceno, Tyler J, Ngo, Kenneth, Zhao, Yutong, Ivanova, Elena V, Bertram, Arrien A, Leeper, Brittaney A, Chambers, Emily S, Adeni, Anika E, Taus, Luke J, Kuraguchi, Mari, Kirschmeier, Paul T, Yu, Channing, Shiose, Yoshinobu, Kamai, Yasuki, Qiu, Yang, Paweletz, Cloud P, Gokhale, Prafulla C, Jänne, Pasi A

“…Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) are the standard-of-care treatment for -mutant non-small cell lung cancers (NSCLC)…”
Get full text

Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer by Bahcall, Magda, Awad, Mark M, Sholl, Lynette M, Wilson, Frederick H, Xu, Man, Wang, Stephen, Palakurthi, Sangeetha, Choi, Jihyun, Ivanova, Elena V, Leonardi, Giulia C, Ulrich, Bryan C, Paweletz, Cloud P, Kirschmeier, Paul T, Watanabe, Masayuki, Baba, Hideo, Nishino, Mizuki, Nagy, Rebecca J, Lanman, Richard B, Capelletti, Marzia, Chambers, Emily S, Redig, Amanda J, VanderLaan, Paul A, Costa, Daniel B, Imamura, Yu, Jänne, Pasi A

“…MET inhibitors can be effective therapies in patients with exon 14 ( ex14) mutant non-small cell lung cancer (NSCLC). However, long-term efficacy is limited by…”
Get full text

Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS by Kitajima, Shunsuke, Asahina, Hajime, Chen, Ting, Guo, Sujuan, Quiceno, Laura Gutierrez, Cavanaugh, Jillian D., Merlino, Ashley A., Tange, Shoichiro, Terai, Hideki, Kim, Jong Wook, Wang, Xiaoen, Zhou, Shan, Xu, Man, Wang, Stephen, Zhu, Zehua, Thai, Tran C., Takahashi, Chiaki, Wang, Yujin, Neve, Richard, Stinson, Susanna, Tamayo, Pablo, Watanabe, Hideo, Kirschmeier, Paul T., Wong, Kwok-Kin, Barbie, David A.

“…Despite extensive efforts, oncogenic KRAS remains resistant to targeted therapy. Combined downstream RAL-TBK1 and MEK inhibition induces only transient lung…”
Get full text

Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer by Kitajima, Shunsuke, Ivanova, Elena, Guo, Sujuan, Yoshida, Ryohei, Campisi, Marco, Sundararaman, Shriram K, Tange, Shoichiro, Mitsuishi, Yoichiro, Thai, Tran C, Masuda, Sayuri, Piel, Brandon P, Sholl, Lynette M, Kirschmeier, Paul T, Paweletz, Cloud P, Watanabe, Hideo, Yajima, Mamiko, Barbie, David A

“…-driven lung cancers frequently inactivate and/or , defining tumor subclasses with emerging clinical relevance. Specifically, - (KL)-mutant lung cancers are…”
Get more information

Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway by Kurppa, Kari J., Liu, Yao, To, Ciric, Zhang, Tinghu, Fan, Mengyang, Vajdi, Amir, Knelson, Erik H., Xie, Yingtian, Lim, Klothilda, Cejas, Paloma, Portell, Andrew, Lizotte, Patrick H., Ficarro, Scott B., Li, Shuai, Chen, Ting, Haikala, Heidi M., Wang, Haiyun, Bahcall, Magda, Gao, Yang, Shalhout, Sophia, Boettcher, Steffen, Shin, Bo Hee, Thai, Tran, Wilkens, Margaret K., Tillgren, Michelle L., Mushajiang, Mierzhati, Xu, Man, Choi, Jihyun, Bertram, Arrien A., Ebert, Benjamin L., Beroukhim, Rameen, Bandopadhayay, Pratiti, Awad, Mark M., Gokhale, Prafulla C., Kirschmeier, Paul T., Marto, Jarrod A., Camargo, Fernando D., Haq, Rizwan, Paweletz, Cloud P., Wong, Kwok-Kin, Barbie, David A., Long, Henry W., Gray, Nathanael S., Jänne, Pasi A.

“…Eradicating tumor dormancy that develops following epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment of EGFR-mutant non-small…”
Get full text

Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade by Sehgal, Kartik, Portell, Andrew, Ivanova, Elena V, Lizotte, Patrick H, Mahadevan, Navin R, Greene, Jonathan R, Vajdi, Amir, Gurjao, Carino, Teceno, Tyler, Taus, Luke J, Thai, Tran C, Kitajima, Shunsuke, Liu, Derek, Tani, Tetsuo, Noureddine, Moataz, Lau, Christie J, Kirschmeier, Paul T, Liu, David, Giannakis, Marios, Jenkins, Russell W, Gokhale, Prafulla C, Goldoni, Silvia, Pinzon-Ortiz, Maria, Hastings, William D, Hammerman, Peter S, Miret, Juan J, Paweletz, Cloud P, Barbie, David A

“…Resistance to oncogene-targeted therapies involves discrete drug-tolerant persister cells, originally discovered through in vitro assays. Whether a similar…”
Get full text

Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance by Bahcall, Magda, Paweletz, Cloud P, Kuang, Yanan, Taus, Luke J, Sim, Taebo, Kim, Nam Doo, Dholakia, Kshiti H, Lau, Christie J, Gokhale, Prafulla C, Chopade, Pratik R, Hong, Fangxin, Wei, Zihan, Köhler, Jens, Kirschmeier, Paul T, Guo, Jiannan, Guo, Sujuan, Wang, Stephen, Jänne, Pasi A

“…MET-targeted therapies are clinically effective in -amplified and exon 14 deletion mutant ( ex14) non-small cell lung cancers (NSCLCs), but their efficacy is…”
Get full text

Recurrent ubiquitin B silencing in gynecological cancers establishes dependence on ubiquitin C by Kedves, Alexia T, Gleim, Scott, Liang, Xiaoyou, Bonal, Dennis M, Sigoillot, Frederic, Harbinski, Fred, Sanghavi, Sneha, Benander, Christina, George, Elizabeth, Gokhale, Prafulla C, Nguyen, Quang-De, Kirschmeier, Paul T, Distel, Robert J, Jenkins, Jeremy, Goldberg, Michael S, Forrester, William C

“…Transcriptional repression of ubiquitin B (UBB) is a cancer-subtype-specific alteration that occurs in a substantial population of patients with cancers of the…”
Get full text

Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cells by Bhanot, H, Reddy, M M, Nonami, A, Weisberg, E L, Bonal, D, Kirschmeier, P T, Salgia, S, Podar, K, Galinsky, I, Chowdary, T K, Neuberg, D, Tonon, G, Stone, R M, Asara, J, Griffin, J D, Sattler, M

“…The rapid proliferation of myeloid leukemia cells is highly dependent on increased glucose metabolism. Through an unbiased metabolomics analysis of leukemia…”
Get full text

Evaluating TBK1 as a therapeutic target in cancers with activated IRF3 by Muvaffak, Asli, Pan, Qi, Yan, Haiyan, Fernandez, Rafael, Lim, Jongwon, Dolinski, Brian, Nguyen, Thi T, Strack, Peter, Wu, Stephen, Chung, Rossana, Zhang, Weiqun, Hulton, Chris, Ripley, Steven, Hirsch, Heather, Nagashima, Kumiko, Wong, Kwok-Kin, Jánne, Pasi A, Seidel-Dugan, Cynthia, Zawel, Leigh, Kirschmeier, Paul T, Middleton, Richard E, Morris, Erick J, Wang, Yan

“…TBK1 (TANK-binding kinase 1) is a noncanonical IκB protein kinase that phosphorylates and activates downstream targets such as IRF3 and c-Rel and, mediates…”
Get full text

Abstract 3157: Serial droplet digital PCR (ddPCR) of plasma cell-free DNA (cfDNA) as pharmacodynamic (PD) biomarker in Phase 1 clinical trials for patients (pts) with KRAS mutant non-small cell lung cancer (NSCLC) by Paweletz, Cloud P., Oxnard, Geoffrey R., Feeney, Nora, Hilton, John F., Gandhi, Leena, Do, Khanh T., Anderson, Adrienne, Wolanski, Andrew, Tejeda, Alexander, English, Jessie M., Kirschmeier, Paul T., Jänne, Pasi A., Shapiro, Geoffrey I.

“…Abstract Introduction: Phase 1 clinical trials of novel therapeutics have historically focused on toxicity, but increasingly are doubling as efficacy studies…”
Get full text

Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids by Jenkins, Russell W, Aref, Amir R, Lizotte, Patrick H, Ivanova, Elena, Stinson, Susanna, Zhou, Chensheng W, Bowden, Michaela, Deng, Jiehui, Liu, Hongye, Miao, Diana, He, Meng Xiao, Walker, William, Zhang, Gao, Tian, Tian, Cheng, Chaoran, Wei, Zhi, Palakurthi, Sangeetha, Bittinger, Mark, Vitzthum, Hans, Kim, Jong Wook, Merlino, Ashley, Quinn, Max, Venkataramani, Chandrasekar, Kaplan, Joshua A, Portell, Andrew, Gokhale, Prafulla C, Phillips, Bart, Smart, Alicia, Rotem, Asaf, Jones, Robert E, Keogh, Lauren, Anguiano, Maria, Stapleton, Lance, Jia, Zhiheng, Barzily-Rokni, Michal, Cañadas, Israel, Thai, Tran C, Hammond, Marc R, Vlahos, Raven, Wang, Eric S, Zhang, Hua, Li, Shuai, Hanna, Glenn J, Huang, Wei, Hoang, Mai P, Piris, Adriano, Eliane, Jean-Pierre, Stemmer-Rachamimov, Anat O, Cameron, Lisa, Su, Mei-Ju, Shah, Parin, Izar, Benjamin, Thakuria, Manisha, LeBoeuf, Nicole R, Rabinowits, Guilherme, Gunda, Viswanath, Parangi, Sareh, Cleary, James M, Miller, Brian C, Kitajima, Shunsuke, Thummalapalli, Rohit, Miao, Benchun, Barbie, Thanh U, Sivathanu, Vivek, Wong, Joshua, Richards, William G, Bueno, Raphael, Yoon, Charles H, Miret, Juan, Herlyn, Meenhard, Garraway, Levi A, Van Allen, Eliezer M, Freeman, Gordon J, Kirschmeier, Paul T, Lorch, Jochen H, Ott, Patrick A, Hodi, F Stephen, Flaherty, Keith T, Kamm, Roger D, Boland, Genevieve M, Wong, Kwok-Kin, Dornan, David, Paweletz, Cloud Peter, Barbie, David A

“…systems that incorporate features of the tumor microenvironment and model the dynamic response to immune checkpoint blockade (ICB) may facilitate efforts in…”
Get more information

Abstract 4515: The anti-CD47 antibody SRF231 increases anti-tumor activity of standard of care chemotherapy in platinum-resistant PDX models of ovarian cancer by Liu, Joyce F., Doshi, Kshama A., Lee, Benjamin H., Peluso, Marisa O., Zhang, Li, Zhou, Shan, Zeng, Qing, Wang, Stephen, Kirschmeier, Paul T., Tran, Cam A., Paweletz, Cloud, Rausch, Matthew, Paterson, Alison M., Gokhale, Prafulla C., Matulonis, Ursula A.

“…Abstract Background: CD47 is a type I integral membrane protein expressed on multiple human tumors, including ovarian cancer, and modulates cell processes such…”
Get full text

Biological Effects and Mechanism of Action of Farnesyl Transferase Inhibitors by Ashar, Hena R, Armstrong, Lydia, James, Linda J, Carr, Donna M, Gray, Kimberley, Taveras, Arthur, Doll, Ronald J, Bishop, W. Robert, Kirschmeier, Paul T

Get full text

Abstract 572: Inhibition of IDO1 with epacadostat enhances anti-tumor efficacy of PD-1 blockade in a syngeneic glioblastoma (GBM) model by Reardon, David A., Gokhale, Prafulla C., Klein, Sarah R., Jones, Kristen L., Kirschmeier, Paul T., Speranza, Maria, Koblish, Holly, Scherle, Peggy, Leopold, Lance, Newton, Robert, Freeman, Gordon J.

“…Abstract Purpose: To determine if epacadostat, an oral indoleamine 2,3-dioxygenase (IDO1) inhibitor has therapeutic benefit against GBM when administered as…”
Get full text

Abstract 372: Optimizing vertical MAPK pathway inhibition for RAS mutant non-small cell lung cancer by Köhler, Jens, Paweletz, Cloud P., Kuang, Yanan, Gokhale, Prafulla, Wilkens, Margaret K., Tiv, Hong, Ogino, Atsuko, Choi, Jihyun, Kirschmeier, Paul T., Jänne, Pasi A.

“…Abstract Introduction: Non-small cell lung tumors (NSCLC) with mutations in genes encoding for Ras proteins (H-, N-, K-Ras) exhibit activation of the MAPK…”
Get full text